Clinical Research Directory
Browse clinical research sites, groups, and studies.
Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART
Sponsor: ANRS, Emerging Infectious Diseases
Summary
The combination of two nucleoside analogues and one protease inhibitor is a highly active antiretroviral therapy (HAART) in HIV infected adults. In those with an undetectable viral load, a once daily combination of FTC, ddI, efavirenz would be easier to take, with less side effects and the same efficacy. The aim of the study was to evaluate if the once daily combination presents the same efficacy than the HAART therapy with less side effects and a better adherence.
Official title: Phase II Randomized Trial Comparing Efficacy and Safety of the Maintenance of a HAART Association Protease Inhibitor Containing Versus a Once Daily Antiretroviral Triple Association, in HIV Adult Patients With Undetectable Viral Load.ANRS 099 ALIZE
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
350
Start Date
2001-04
Completion Date
2004-09
Last Updated
2026-06-15
Healthy Volunteers
No
Conditions
Interventions
emtricitabine, FTC (drug)
didanosine, ddI (drug)
efavirenz (drug)
Locations (1)
Service de Maladies Infectieuses, Hôpital Saint-Louis
Paris, France